Zika virus (ZIKV) emerged at a global level when it spread to the Americas and began causing congenital malformations and microcephaly in 2015. A rapid response by academia, government, public health infrastructure, and industry has enabled the expedited development and testing of a suite of vaccine platforms aiming to control and eliminate ZIKV-induced disease. Analysis of key immunization and pathogenesis studies in multiple animal models, including during pregnancy, has begun to define immune correlates of protection. Nonetheless, the deployment of ZIKV vaccines, along with the confirmation of their safety and efficacy, still has major challenges, one of which is related to the waning of the epidemic. In this review, we discuss the measures that enabled rapid progress and highlight the path forward for successful deployment of ZIKV vaccines.

Original languageEnglish
Pages (from-to)121-135
Number of pages15
JournalAnnual review of medicine
StatePublished - Jan 27 2019


  • ZIKV
  • Zika virus
  • antibody
  • antibody-dependent enhancement
  • dengue virus
  • flavivirus
  • neutralization
  • vaccine


Dive into the research topics of 'Zika virus vaccine development: Progress in the face of new challenges'. Together they form a unique fingerprint.

Cite this